Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Comparing Tolerability and Toxicity of Calaspargase pegol and Pegaspargase in Pediatric Leukemia Patients

View through CrossRef
ABSTRACT:   Background: Pegaspargase (PEG-ASP) and calaspargase pegol (CAL-PEG) are long acting asparaginase formulations used to treat acute leukemia. As of December 2022, CAL-PEG became the standard formulation for pediatric patients less than 22 years of age. The objective of this study was to compare real-world safety and efficacy of the two formulations in pediatric patients at a single institution.       Procedure:  A three-year retrospective evaluation of PEG-ASP and CAL-PEG utilization was completed. Patients treated at stand-alone children’s hospital for acute leukemia who received at least one dose of long acting asparaginase therapy were included. Incidence and severity of hypersensitivity reactions, silent inactivation, thromboembolism, bleeding, pancreatitis, hepatotoxicity, and hypertriglyceridemia were collected.   Results: A total of 103 patients were included, of whom 50 received CAL-PEG and 58 received PEG-ASP. In the CAL-PEG group, 10 patients experienced a symptomatic hypersensitivity reaction, compared to six patients in the PEG-ASP group (20.0% vs. 10.3%; p = 0.16). Eight patients receiving CAL-PEG had a silent inactivation while compared to three patients receiving PEG-ASP (16.0% vs. 5.2%; p = 0.18). There was a higher rate of hyperbilirubinemia noted with PEG-ASP compared to CAL-PEG (58.6% vs. 34.0%; p = 0.01). Other adverse effects, including hypertriglyceridemia, thrombosis, bleeding, transaminitis, and pancreatitis were comparable between the two groups.     Conclusions: There were no significant differences found between CAL-PEG and PEG-ASP in terms of hypersensitivity reactions and silent inactivation. Most other adverse effects associated with asparaginase therapy were also similar between the two groups. Monitoring and preventative measures should continue for patients to help prevent the adverse effects associated with CAL-PEG.
Title: Comparing Tolerability and Toxicity of Calaspargase pegol and Pegaspargase in Pediatric Leukemia Patients
Description:
ABSTRACT:   Background: Pegaspargase (PEG-ASP) and calaspargase pegol (CAL-PEG) are long acting asparaginase formulations used to treat acute leukemia.
As of December 2022, CAL-PEG became the standard formulation for pediatric patients less than 22 years of age.
The objective of this study was to compare real-world safety and efficacy of the two formulations in pediatric patients at a single institution.
      Procedure:  A three-year retrospective evaluation of PEG-ASP and CAL-PEG utilization was completed.
Patients treated at stand-alone children’s hospital for acute leukemia who received at least one dose of long acting asparaginase therapy were included.
Incidence and severity of hypersensitivity reactions, silent inactivation, thromboembolism, bleeding, pancreatitis, hepatotoxicity, and hypertriglyceridemia were collected.
  Results: A total of 103 patients were included, of whom 50 received CAL-PEG and 58 received PEG-ASP.
In the CAL-PEG group, 10 patients experienced a symptomatic hypersensitivity reaction, compared to six patients in the PEG-ASP group (20.
0% vs.
10.
3%; p = 0.
16).
Eight patients receiving CAL-PEG had a silent inactivation while compared to three patients receiving PEG-ASP (16.
0% vs.
5.
2%; p = 0.
18).
There was a higher rate of hyperbilirubinemia noted with PEG-ASP compared to CAL-PEG (58.
6% vs.
34.
0%; p = 0.
01).
Other adverse effects, including hypertriglyceridemia, thrombosis, bleeding, transaminitis, and pancreatitis were comparable between the two groups.
    Conclusions: There were no significant differences found between CAL-PEG and PEG-ASP in terms of hypersensitivity reactions and silent inactivation.
Most other adverse effects associated with asparaginase therapy were also similar between the two groups.
Monitoring and preventative measures should continue for patients to help prevent the adverse effects associated with CAL-PEG.

Related Results

Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract Abstract 1606 Introduction: Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
BACKGROUND: A workforce analysis was conducted to predict whether the projected future supply of pediatric anesthesiologists is balanced with the requirements o...
ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,
ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,
Abstract Abstract 3905 ROR1 is a receptor tyrosine kinase-like orphan receptor and an oncofetal protein that is expressed on chronic lymphocytic leuke...
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
BACKGROUND: The geographic relationship between pediatric anesthesiologists and the pediatric population has potentially important clinical and policy implicati...

Back to Top